Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Compare long-run outcomes for index versus active strategies, emphasizing time horizons, persistence of outperformance, and practical takeaways.
27,723 articlesNovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Veteran investors known for patient, low-turnover strategies are guiding portfolios as markets drift higher. This pie...
Developed international value stocks are trading at discounts outside the U.S., and the Fidelity International Value ...
A major sports policy change bars transgender women from competing in women's events. This decision carries far more ...
Many investors chase cash flow in a low-yield market. This guide highlights three high-yield stocks that could help b...
The 2026 mortgage update signals a turning tide for borrowers. Lower rates and the return of adjustable-rate mortgage...
Real estate ETFs give you exposure to property markets without being a landlord. This guide compares REET and VNQ, fo...
One large investor dumped 783,379 Truth Social shares, triggering a sharp move in the stock. This article explains wh...
Income-focused investing is making waves in 2026. This high-yielding dividend beating ETF has shown resilience as bro...
Retirees are increasingly building a dividend-driven portfolio that funds two annual cruises while keeping principal ...
A major TV move—Jennifer Aniston reportedly exits an Apple series—highlights how gig income, contracts, and risk affe...
Investors swing between growth and value stocks as markets swing from tech optimism to defensive plays. This guide br...